Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia

John B. Christoforidis; Daniel J. DeAngelo; Donald J. D'Amico

doi:10.1016/S0002-9394(02)01964-5

Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia

John B. Christoforidis, Daniel J. DeAngelo, Donald J. D'Amico

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

PURPOSE: To report a case of leukemic retinopathy before and after treatment with imatinib mesylate (formerly STI-571) for chronic myelogenous leukemia (CML). DESIGN: Interventional case report. METHODS: A 58-year-old man diagnosed with stable phase CML (SP-CML) presented with blurry vision. Fundoscopy revealed several flame-shaped hemorrhages in the macular region in both eyes. One month after this initial visit, imatinib therapy was initiated. RESULTS: The patient noticed improvement in his visual as well as his medical symptoms; on repeat examination 6 months after the initial visit, the retinal hemorrhages had resolved and remained so after 18 months. CONCLUSIONS: Imatinib appears to be an effective treatment for SP-CML, and the improvement in visual and medical symptoms in our case report correlates with this.

Original language	English (US)
Pages (from-to)	398-400
Number of pages	3
Journal	American Journal of Ophthalmology
Volume	135
Issue number	3
DOIs	https://doi.org/10.1016/S0002-9394(02)01964-5
State	Published - Mar 1 2003
Externally published	Yes

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/S0002-9394(02)01964-5

Cite this

@article{5212ad8ae7e64b5f9c0f728cf01fb26b,

title = "Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia",

abstract = "PURPOSE: To report a case of leukemic retinopathy before and after treatment with imatinib mesylate (formerly STI-571) for chronic myelogenous leukemia (CML). DESIGN: Interventional case report. METHODS: A 58-year-old man diagnosed with stable phase CML (SP-CML) presented with blurry vision. Fundoscopy revealed several flame-shaped hemorrhages in the macular region in both eyes. One month after this initial visit, imatinib therapy was initiated. RESULTS: The patient noticed improvement in his visual as well as his medical symptoms; on repeat examination 6 months after the initial visit, the retinal hemorrhages had resolved and remained so after 18 months. CONCLUSIONS: Imatinib appears to be an effective treatment for SP-CML, and the improvement in visual and medical symptoms in our case report correlates with this.",

author = "Christoforidis, {John B.} and DeAngelo, {Daniel J.} and D'Amico, {Donald J.}",

note = "Funding Information: Supported in part by the Vitreoretinal Research Fund (Dr. D{\textquoteright}Amico) and by the Iacocca Foundation. ",

year = "2003",

month = mar,

day = "1",

doi = "10.1016/S0002-9394(02)01964-5",

language = "English (US)",

volume = "135",

pages = "398--400",

journal = "American Journal of Ophthalmology",

issn = "0002-9394",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia

AU - Christoforidis, John B.

AU - DeAngelo, Daniel J.

AU - D'Amico, Donald J.

N1 - Funding Information: Supported in part by the Vitreoretinal Research Fund (Dr. D’Amico) and by the Iacocca Foundation.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - PURPOSE: To report a case of leukemic retinopathy before and after treatment with imatinib mesylate (formerly STI-571) for chronic myelogenous leukemia (CML). DESIGN: Interventional case report. METHODS: A 58-year-old man diagnosed with stable phase CML (SP-CML) presented with blurry vision. Fundoscopy revealed several flame-shaped hemorrhages in the macular region in both eyes. One month after this initial visit, imatinib therapy was initiated. RESULTS: The patient noticed improvement in his visual as well as his medical symptoms; on repeat examination 6 months after the initial visit, the retinal hemorrhages had resolved and remained so after 18 months. CONCLUSIONS: Imatinib appears to be an effective treatment for SP-CML, and the improvement in visual and medical symptoms in our case report correlates with this.

AB - PURPOSE: To report a case of leukemic retinopathy before and after treatment with imatinib mesylate (formerly STI-571) for chronic myelogenous leukemia (CML). DESIGN: Interventional case report. METHODS: A 58-year-old man diagnosed with stable phase CML (SP-CML) presented with blurry vision. Fundoscopy revealed several flame-shaped hemorrhages in the macular region in both eyes. One month after this initial visit, imatinib therapy was initiated. RESULTS: The patient noticed improvement in his visual as well as his medical symptoms; on repeat examination 6 months after the initial visit, the retinal hemorrhages had resolved and remained so after 18 months. CONCLUSIONS: Imatinib appears to be an effective treatment for SP-CML, and the improvement in visual and medical symptoms in our case report correlates with this.

UR - http://www.scopus.com/inward/record.url?scp=0344089315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344089315&partnerID=8YFLogxK

U2 - 10.1016/S0002-9394(02)01964-5

DO - 10.1016/S0002-9394(02)01964-5

M3 - Article

C2 - 12614767

AN - SCOPUS:0344089315

SN - 0002-9394

VL - 135

SP - 398

EP - 400

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

IS - 3

ER -

Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this